Delving into the Latest Updates on Pilsicainide Hydrochloride Hydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Alisrythm, Pilsicainide, Pilsicainide Hydrochloride

+ [13]

Target

Sodium channels

Mechanism

Sodium channels blockers

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Arrhythmias, Cardiac

Inactive Indication-

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization

Daiichi Sankyo Korea Co., Ltd.

Daiichi Sankyo Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (29 Mar 1991),

Arrhythmias, Cardiac

Regulation-

Login to view timeline

Structure

Molecular FormulaC17H24N2O

InChIKeyBCQTVJKBTWGHCX-UHFFFAOYSA-N

CAS Registry88069-67-4

View All Structures (2)

The multicenter study of rhythm-control drugs in patients with paroxysmal atrial fibrillation: Comparison of the efficacy of flecainide or pilsicainide in patients with symptomatic paroxysmal atrial fibrillation - The multicenter study of rhythm-control drugs in patients with paroxysmal atrial fibrillation

Start Date01 Aug 2011

Sponsor / Collaborator-

100 Clinical Results associated with Pilsicainide Hydrochloride Hydrate

Login to view more data

100 Translational Medicine associated with Pilsicainide Hydrochloride Hydrate

Login to view more data

100 Patents (Medical) associated with Pilsicainide Hydrochloride Hydrate

Login to view more data

263

Literatures (Medical) associated with Pilsicainide Hydrochloride Hydrate

01 Oct 2024·Heart Rhythm

Risk stratification for the occurrence of ventricular fibrillation in patients with early repolarization syndrome

Article

Author: Nishii, Nobuhiro ; Kawada, Satoshi ; Ueoka, Akira ; Mizuno, Tomofumi ; Yuasa, Shinsuke ; Nakagawa, Koji ; Masuda, Takuro ; Asada, Saori ; Morita, Hiroshi ; Miyamoto, Masakazu

BACKGROUNDSeveral signs of malignant early repolarizations have been proposed in patients with early repolarization syndrome (ERS). However, reports have challenged the efficacy of these signs in predicting future ventricular fibrillation (VF) in patients with ERS.OBJECTIVEThis study aimed to assess the predictive value of various electrocardiogram (ECG) markers for future VF events in patients with ERS.METHODSWe retrospectively evaluated the clinical characteristics of 44 patients with ERS to identify risk factors for VF during follow-up.RESULTSAfter the initial event, 16 patients experienced VF (VF group), whereas 28 did not (non-VF group). The VF group had a longer QRS interval, more fragmented QRS (fQRS), and a higher T/R voltage ratio than the non-VF group. Wide J waves were more prevalent in the VF group; however, other J-wave markers did not differ between the groups. Positive late potentials recorded on signal-averaged ECGs were more frequent in the VF group. Whereas none of the patients showed spontaneous Brugada syndrome on ECG, the VF group frequently exhibited pilsicainide-induced ST-segment elevation. These ECG markers were significantly associated with the occurrence of VF during follow-up. Patients with multiple ECG factors, including QRS abnormalities (wide QRS or fQRS), wide J waves, and a high T/R ratio, had a worse prognosis than patients without multiple factors, effectively stratifying patient risk.CONCLUSIONThe occurrence of VF in patients with ERS may be associated with conduction abnormalities such as QRS widening, fQRS, high T/R ratio, positive late potentials, and pilsicainide test results. Therefore, ECG factors could be useful in identifying high-risk patients.

01 Sep 2024·Journal of Pharmacological Sciences

Characterization of remodeling processes in the atria of atrioventricular block dogs: Utility as an early-stage atrial fibrillation model

Article

Author: Akie, Yasuki ; Kambayashi, Ryuichi ; Sugiyama, Atsushi ; Takahara, Akira ; Hori, Masaaki ; Goto, Ai ; Saito, Hiroyuki ; Izumi-Nakaseko, Hiroko ; Takei, Yoshinori

To characterize utility of atrioventricular block (AVB) dogs as atrial fibrillation (AF) model, we studied remodeling processes occurring in their atria in acute (<2 weeks) and chronic (>4 weeks) phases. Fifty beagle dogs were used. Holter electrocardiogram demonstrated that paroxysmal AF occurred immediately after the production of AVB, of which duration tended to be prolonged in chronic phase. Electrophysiological analysis showed that inter-atrial conduction time and duration of burst pacing-induced AF increased in the chronic phase compared with those in the acute phase, but that atrial effective refractory period was hardly altered. Echocardiographic study revealed that diameters of left atrium, right pulmonary vein and inferior vena cava increased similarly in the acute and chronic phases. Histological evaluation indicated that hypertrophy and fibrosis in atrial tissue increased in the chronic phase. Electropharmacological characterization showed that i.v. pilsicainide effectively suppressed burst pacing-induced AF with increasing atrial conduction time and refractoriness of AVB dogs in chronic phase, but that i.v. amiodarone did not exert such electrophysiological effects. Taken together, AVB dogs in chronic phase appear to possess such pathophysiology as developed in the atria of early-stage AF patients, and therefore they can be used to evaluate drug candidates against early-stage AF.

20 Aug 2024·Circulation

Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?

Review

Author: Amin, Ahmad S. ; Chorin, Ehud ; Wilde, Arthur A. ; Viskin, Sami ; Rosso, Raphael

Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to diagnose or exclude Brugada syndrome and, perhaps more importantly, who should not. We present a critical review of the benefits and drawbacks of the SCB challenge when performed in cardiac arrest survivors, patients presenting with syncope, family members of probands with confirmed Brugada syndrome, and asymptomatic patients with suspicious ECG.

100 Deals associated with Pilsicainide Hydrochloride Hydrate

Login to view more data